Laquinimod - Active Biotech

Drug Profile

Laquinimod - Active Biotech

Alternative Names: ABR-215062; Laquinimod sodium; Nerventra; SAIK-MS; TV-5600

Latest Information Update: 07 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Icahn School of Medicine at Mount Sinai; National University of Singapore; Ruhr-University Bochum; Tel Aviv University; University College London; University of British Columbia
  • Class Anti-inflammatories; Neuropsychotherapeutics; Quinolones; Small molecules
  • Mechanism of Action Aryl hydrocarbon receptor agonists; Brain-derived neurotrophic factor expression stimulants; Immunomodulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase II Huntington's disease
  • Discontinued Crohn's disease; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 05 Sep 2018 Laquinimod is no longer licensed to Teva Pharmaceutical Industries worldwide
  • 24 Jun 2018 Biomarkers information updated
  • 19 Jun 2018 Teva Branded Pharmaceutical Products completes the phase II LEGATO-HD trial in Huntington's disease in USA, United Kingdom, Canada, Portugal, the Czech Republic, Germany, Italy, Netherlands, Russia and Spain(NCT02215616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top